Skip to content

Dossier · BAK · Dormant

BAK

Last analysed · · source: watchlist_research

Current thesis

Deep-cyclical Brazilian petrochem, NOT a momentum name. Only live angle is the perennial Novonor stake-sale + Braskem Idesa debt-restructuring binary. Nothing accelerating now; the Q1 print (2026-05-13) bounce already faded. Skip until a concrete M&A/restructuring headline prints on volume.

Invalidation trigger

No long thesis to invalidate — posture is SKIP. A would-be event bounce is dead if: Braskem Idesa creditor/bankruptcy-loan deal collapses, OR Novonor stake-sale is again shelved, OR BAK weekly close below ~$3 ADR support (est.). Any of these = stay flat.

Thesis status

Open commitment scored if the trigger above fires How this is scored →

Current Thesis

Braskem is a deep-cyclical Brazilian petrochemical producer (PE/PP/PVC), the largest in the Americas — this is not a narrative-momentum vehicle. It is a debt-heavy, spread-compressed commodity name that the prior pipeline mis-tagged into "commodity-materials-rare-earths" (it has nothing to do with rare earths). The only tradable narrative is a distressed/event-driven binary: the perennial Novonor (ex-Odebrecht) controlling-stake sale and the Braskem Idesa (Mexico JV) debt restructuring. Q1 2026 printed 2026-05-13; BAK popped on a "better-than-expected" headline (2026-05-12) but that is a dead-cat in a structural downcycle, not an accelerating leg. Default posture: SKIP / stay flat. There is no cluster of peers breaking out, no ACCELERATING theme, no fresh catalyst inside 30 days.

Bull Case

  • Stake-sale optionality (event-driven). Novonor has spent years trying to exit its controlling stake; ADNOC/Apollo-type strategics have circled repeatedly. Any concrete bid re-rates a beaten-down distressed equity violently off the lows. This is the entire bull case.
  • Braskem Idesa creditor deal near. 2026-05-13 (Bloomberg): "Braskem Idesa, Creditors Near Deal for Bankruptcy Loan" — a financing backstop removes a tail-risk overhang on the Mexico JV. Resolution of distress, not growth, is the catalyst.
  • Q1 2026 beat / guidance pop. 2026-05-12 Benzinga: BAK among names "moving higher on better-than-expected financial results and guidance." Petrochemical spreads off the absolute bottom would give operating leverage on a highly cyclical cost base.
  • Deep-value / mean-reversion. Trades as a low-priced ADR (~$3–5 range, est.) — heavily out of favor; small narrative shift moves it on percentage terms.

Bear Case

  • No accelerating narrative — fails the playbook's one test. Strength is the setup here; BAK has no strength leg, no peer cluster, no sell-side acceleration ahead of us.
  • Structural balance-sheet distress. A bankruptcy loan negotiation at Braskem Idesa (2026-05-13) is a distress signal, not a green light. Leverage + compressed global petrochem spreads = secular headwind.
  • Commodity price-taker. Earnings are a function of naphtha/ethane vs polyethylene spreads and BRL — no proprietary moat, no narrative velocity to ride.
  • Value-trap risk. Cheap multiple + rolled-over tape = exactly the trap the playbook flags. Cost-basis anchoring and "it'll come back" are how this name kills accounts.
  • Catalyst already passed. Q1 (2026-05-13) is behind us; the bounce faded. Next scheduled print is Q2 ~August — nothing inside 30 days to drive a move.

Setup & Price Structure

Low-priced distressed ADR (est. ~$3–5; no price context was provided this run — verify live before any action). Structure is a downcycle base/value-trap, not a momentum breakout. No higher-low sequence confirming a new uptrend, no MA stack to ride. This is the textbook "cheap multiple + dead/broken tape" the playbook says to avoid. If anything tradable develops it would be an event-gap (M&A headline) you chase intraday on confirmation, not a trend you accumulate. Do not average down — there is no thesis to defend on weakness.

Catalyst Calendar (next 30 days)

  • Braskem Idesa bankruptcy-loan / creditor dealongoing, no fixed date; "near deal" as of 2026-05-13. Headline-driven, could land any week; watch the tape, don't pre-position.
  • Novonor controlling-stake saleno scheduled date; recurring M&A overhang, only matters on a concrete bid headline.
  • Q1 2026 earnings — already reported 2026-05-13 (call transcript 2026-05-15). No earnings binary inside the window; Q2 ~August.
  • No PDUFA / no upgrade cluster / no insider-buy cluster on file.

What Would Change Our Mind

We'd flip from SKIP to a probe only if: (1) a concrete Novonor stake-sale bid or ADNOC/strategic offer is reported and BAK gaps on volume — chase the confirmed event, not the rumor; OR (2) Braskem Idesa restructuring formally closes AND BAK reclaims a multi-week high with petrochem-peer confirmation (LYB, DOW, WLK also turning). Absent a hard event, no amount of "cheapness" earns a position.

Correlation Notes

Trades with global petrochemical spreads (LYB, DOW, WLK, Westlake), crude/naphtha, and BRL/EM-Brazil risk (correlates loosely with PBR, EWZ, BVSP). NOT correlated with the rare-earths / critical-materials theme it was erroneously bucketed into — operator action: re-tag away from "commodity-materials-rare-earths." Idiosyncratic driver is Braskem-specific credit/M&A headlines, which can decouple it from the petrochem complex on event days.

[operator note] Theme membership was wrong (rare-earths). This is a Brazilian petrochemical / distressed-credit name. Keep DORMANT until a hard event prints.